Laura Soucek is ICREA Research Professor, Director of the Experimental Therapeutics Research Program and Head of the Models of Cancer Therapies Laboratories at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain. In addition, she is Associate Professor at the Universitat Autonoma de Barcelona and CEO and co-founder of Peptomyc S.L. She graduated in Biological Sciences in 1996 and obtained her PhD in Genetics and Molecular Biology in 2001 at the University La Sapienza, Rome, Italy. She did her postdoc at University California San Francisco (UCSF; 2001-2006), where she was then promoted to Assistant Researcher (2006-2011). She has been leading her research laboratory at VHIO in Barcelona since then.

Laura is a key opinion leader in MYC biology and MYC inhibition, as well the developer of the most characterized MYC inhibitor known to date, Omomyc, which is the first MYC inhibitor to have successfully completed a Phase Iclinical trial and is now in Phase Ib/II studies.

She is member of the Spanish Society of Biochemistry and Molecular Biology (SEBBM), the Spanish Association for Cancer Research (ASEICA), the American Association for Cancer Research (AACR) and WICR (Women in Cancer Research).